<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rivastigmine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00989</strong>&#160; (APRD00321)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer&#8217;s type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00989/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00989/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00989.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00989.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00989.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00989.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00989.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00989">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ena 713 Free Base</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Exelon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Exelon Patch</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/neuroprotective-agents">Neuroprotective Agents</a></li>
<li><a href="/mesh/cholinesterase-inhibitors">Cholinesterase Inhibitors</a></li>
<li><a href="/mesh/cholinergic-agents">Cholinergic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>123441-03-2</td></tr><tr><th>Weight</th><td>Average: 250.3367<br>Monoisotopic: 250.168127958</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>XSVMFMHYUFZWBK-NSHDSACASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Phenethylamines</td></tr><tr><th>Alternative parents</th><td>Phenol Ethers; Tertiary Amines; Carbamic Acids and Derivatives; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>phenol ether; carbamic acid derivative; tertiary amine; polyamine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.</td></tr><tr><th>Pharmacodynamics</th><td>Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.</td></tr><tr><th>Mechanism of action</th><td>Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.8 to 2.7 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>40%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.</p></td></tr><tr><th>Route of elimination</th><td>Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.</td></tr><tr><th>Half life</th><td>1.5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>renal cl=2.1-2.8 L/hr</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9853</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7001</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6571</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7919</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8756</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8406</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7993</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6659</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5932</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.609</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8928</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8384</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8734</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9545</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8062</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5279
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5858
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9463
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4167 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9355
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8986
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li>
<li>Dr reddys laboratories inc</li>
<li>Sun pharmaceutical industries ltd</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.ltslohmann.com">LTS Lohmann Therapy Systems Corp.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Exelon 30 4.6 mg/24hr Patches Box</td><td>252.18USD</td><td>box</td></tr><tr><td>Exelon 30 9.5 mg/24hr Patches Box</td><td>252.18USD</td><td>box</td></tr><tr><td>Exelon 4.6 mg/24hr patch</td><td>8.08USD</td><td>patch</td></tr><tr><td>Exelon 9.5 mg/24hr patch</td><td>8.08USD</td><td>patch</td></tr><tr><td>Exelon 1.5 mg capsule</td><td>4.81USD</td><td>capsule</td></tr><tr><td>Exelon 3 mg capsule</td><td>4.81USD</td><td>capsule</td></tr><tr><td>Exelon 4.5 mg capsule</td><td>4.81USD</td><td>capsule</td></tr><tr><td>Exelon 6 mg capsule</td><td>4.81USD</td><td>capsule</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6316023</td><td>1999-01-08</td><td>2019-01-08</td></tr><tr><td>United States</td><td>4948807</td><td>1992-08-14</td><td>2012-08-14</td></tr><tr><td>Canada</td><td>2315784</td><td>2006-06-27</td><td>2019-01-08</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>2.3</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.04e+00 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.45</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.41</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.89</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>32.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>73.37</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>28.53</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Venkata Naga Brahmeswara Rao Mandava, Venkata Reddy Vajrala, Ganesh Varanasi, Vijay Kumar Adla, Mukund Reddy Jambula, Vijaypal Reddy Kanumathi Reddy, &#8220;<span class="caps">PREPARATION</span> OF <span class="caps">RIVASTIGMINE</span> <span class="caps">AND</span> <span class="caps">ITS</span> <span class="caps">SALTS</span>.&#8221; U.S. Patent US20080255383, issued October 16, 2008.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20080255383&amp;tbm=pts" target="_blank">US20080255383 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer&#8217;s disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12369954">Pubmed</a></li>
	<li>Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer&#8217;s disease: international randomised controlled trial. <span class="caps">BMJ</span>. 1999 Mar 6;318(7184):633-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10066203">Pubmed</a></li>
	<li>Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer&#8217;s disease. Clin Ther. 2004 Jul;26(7):980-90. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15336465">Pubmed</a></li>
	<li>Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer&#8217;s disease. Behav Neurol. 1998;11(4):211-216. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11568422">Pubmed</a></li>
	<li>Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson&#8217;s disease. N Engl J Med. 2004 Dec 9;351(24):2509-18. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15590953">Pubmed</a></li>
	<li>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer&#8217;s disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19370562">Pubmed</a># Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19470293">Pubmed</a></li>
	<li>Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14587496">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D03822" target="_blank">D03822 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C11766" target="_blank">C11766 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=77991" target="_blank">77991 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507452" target="_blank">46507452 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.70377.html" target="_blank">70377 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10620" target="_blank">10620 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000149" target="_blank">DAP000149 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451262" target="_blank">PA451262 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2242118" target="_blank">2242118 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/rivastig.htm" target="_blank">http://www.rxlist.com/cgi/generic2/rivastig.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/rivastigmine.html" target="_blank">http://www.drugs.com/cdi/rivastigmine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Rivastigmine" target="_blank">Rivastigmine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N06DA03<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N06#N06">N06 &#8212; PSYCHOANALEPTICS</a></li><li><a href="/atc/N06D#N06D">N06D &#8212; ANTI-DEMENTIA DRUGS</a></li><li><a href="/atc/N06DA#N06DA">N06DA &#8212; Anticholinesterases</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>12:04.00</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1P0Q" target="_blank">1P0Q <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00989.pdf?1265922808">show</a>(74 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00915">Amantadine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00719">Azatadine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00245">Benzatropine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00810">Biperiden</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00835">Brompheniramine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01114">Chlorphenamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01239">Chlorprothixene</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00283">Clemastine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01176">Cyclizine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00924">Cyclobenzaprine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00434">Cyproheptadine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00804">Dicyclomine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00985">Dimenhydrinate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01075">Diphenhydramine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01148">Flavoxate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00875">Flupentixol</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01437">Glutethimide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00986">Glycopyrrolate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00557">Hydroxyzine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00424">Hyoscyamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00408">Loxapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00737">Meclizine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00334">Olanzapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01173">Orphenadrine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01062">Oxybutynin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01608">Propericiazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01622">Thioproperazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00376">Trihexyphenidyl</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>